Back to top

Recursion Pharmaceuticals (RXRX) Gets a Hold from Morgan Stanley

Morgan Stanley analyst Sean Laaman maintained a Hold rating on Recursion Pharmaceuticals today and set a price target of $5.30. Laaman covers the H...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Recursion Pharmaceuticals, Inc. (RXRX)